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Abstract
Introduction Receptor radionuclide therapy is a promising
treatment modality for patients with neuroendocrine tumors
for whom alternative treatments are limited. The aim of this
study was to investigate the incidence of hormonal crises
after therapy with the radiolabeled somatostatin analogue
[
177Lu-DOTA
0,Tyr
3]octreotate (
177Lu-octreotate).
Materials and methods All
177Lu-octreotate treatments
between January 2000 and January 2007 were investigated.
Four hundred seventy-six patients with gastroenteropancre-
atic neuroendocrine tumors and three patients with meta-
static pheochromocytoma were included for analysis.
Results Four hundred seventy-nine patients received a total
of 1,693 administrations of
177Lu-octreotate. Six of 479
patients (1%) developed severe symptoms because of
massive release of bioactive substances after the first cycle
of
177Lu-octreotate. One patient had a metastatic hormone-
producing small intestinal carcinoid; two patients had
metastatic, hormone-producing bronchial carcinoids; two
patients had vasoactive intestinal polypeptide-producing
pancreatic endocrine tumors (VIPomas); and one patient
had a metastatic pheochromocytoma. With adequate treat-
ment, all patients eventually recovered.
Conclusion Hormonal crises after
177Lu-octreotate therapy
o c c u ri n1 %o fp a t i e n t s .G e n e r a l l y ,
177Lu-octreotate therapy is
well tolerated.
Keywords Lu-177-octreotate.Neuroendocrinetumors.
Peptidereceptorradionuclidetherapy.Carcinoidcrisis
Introduction
Gastroenteropancreatic neuroendocrine tumors (GEPNETs)
constitute a heterogeneous group of neoplasms. Two major
GEPNET subcategories are intestinal endocrine tumors or
carcinoids and pancreatic neuroendocrine tumors (PNETs).
These tumors are often slow growing and may be associated
with typical symptoms because of excessive and uncon-
trolled release of various metabolically active amines and
peptides, such as serotonin, gastrin, glucagon, somatostatin,
insulin, vasoactive intestinal polypeptide (VIP), and sub-
stance P. Pheochromocytomas are catecholamine-producing
tumors, which generally arise in the adrenal medulla.
A so-called carcinoid crisis is a medical emergency
caused by the excessive release of metabolically active
amines or peptides that can occur spontaneously after
manipulation of a carcinoid tumor, during induction of
anesthesia,duringsurgery,endoscopy,orwithchemotherapy
[1–5]. The symptomatology involves profound flushing,
hypotension, or extreme changes in blood pressure,
diarrhea, bronchoconstriction, and arrhythmias [6]. So far,
only one case of a carcinoid crisis after therapy with a
radiolabeled somatostatin analogue has been described [7].
Another well-recognized endocrine emergency can occur in
patients with pheochromocytomas. This is caused by the
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spontaneously, after manipulation of the tumor or during
medical interventions [8].
Since the year 2000, patients with somatostatin receptor-
positive metastatic, inoperable GEPNETs and malignant
pheochromocytomas have been treated with the radiolabeled
somatostatin analogue [
177Lu-DOTA
0,T y r
3]octreotate
(
177Lu-octreotate) in our institution. Results of
177Lu-
octreotate treatment in these patients are promising, with
tumor size reduction in 47% of the treated patients [9].
Although infrequent, hormonal release-induced crises
can occur after
177Lu-octreotate treatment. In this study, we
describe all patients who developed a hormonal crisis in
association with peptide receptor radionuclide therapy with
177Lu-octreotate.
Materials and methods
Patients
All patients with neuroendocrine tumors treated in our
institution treated with
177Lu-octreotate between January
2000 and January 2007 were included in this study. All
patients fulfilled the inclusion criteria for
177Lu-octreotate
therapy [9]. All patients gave written informed consent to
undergo
177Lu-octreotate therapy. This therapy was approved
by the medical ethical committee of our hospital.
Methods
177Lu-octreotate was prepared as described previously [10].
Somatostatin analogue therapy was discontinued in 193
of 200 patients during
177Lu-octreotate therapy. Long-
acting somatostatin analogues (Sandostatin LAR, Lanreotide
Autogel) were discontinued 1 month before therapy. There-
after, therapy was switched to an immediate release
somatostatin analogue (Octreotide) that was discontinued
1 day before
177Lu-octreotate therapy. An infusion of amino
acids (2.5% arginine, 2.5% lysine 1 l/4 h) was administered
to reduce the radiation dose to the kidneys, starting 30 min
before administration of 7,400 MBq
177Lu-octreotate.
Generally, four cycles of
177Lu-octreotate were given.
Routine hematology and liver and kidney function tests,
as well as serum chromogranin A measurements (CgA),
were performed before each therapy cycle in all patients.
Additionally, 5-hydroxy-indole-acid (5HIAA) measure-
ments in 24-h urine in the carcinoid patients, serum
vasoactive intestinal peptide in the VIPoma patients, serum
gastrin in gastrinoma patients, and excretion of normeta-
nephrines and metanephrines in the 24-h urine in the patients
with a metastatic pheochromocytoma were measured (labo-
ratory normal values: CgA<100 μg/l, 5HIAA<50 μmol/
24 h, VIP 25–65 pg/ml, gastrin<0.15 μg/l, metanephrines<
2 μmol/24 h, normetanephrines<5.1 μmol/24 h).
Results
Patient characteristics
Four hundred seventy-nine patients with neuroendocrine
tumors were studied: 262 men (55%), and 217 women
(45%).Twohundred sixty-five patients (53%) had metastatic
carcinoid tumors: 52 patients (11%) had metastatic neuro-
endocrinetumorsofunknownorigin,124patients (26%) had
non-functioning PNETs, 35 patients (7%) had functioning
PNETs, and 3 patients (1%) had metastatic pheochromocy-
toma. The mean age at the time of the first therapy was
56 years (range, 16–85), and the mean Karnofsky perfor-
mance score was 90 (range, 50–100). The tumor burden in
the majority of the patients was high with liver metastases in
88% and bone metastases in 26% of the patients. Before
177Lu-octreotate therapy, 42% of patients were using
somatostatin analogues to reduce hormonal symptoms.
Patient characteristics are shown in Table 1.
Therapy and complications
The 479 patients received a total of 1,693 administrations
of
177Lu-octreotate. Mild side effects within 24 h after
177Lu-octreotate therapy were nausea after 25%, vomiting
after 10%, and increase of abdominal pain/discomfort after
9% of the treatment cycles.
After 10 of 1,691 (0.6%) administrations of
177Lu-
octreotate in six patients (1%), readmission or prolonged
hospitalization because of hormonal release-induced crisis
was necessary. Two of 20 patients with bronchial carci-
noids, 2 of 3 patients with a VIPoma, 1 of 241 patients with
a digestive tract carcinoid, and 1 of 3 patients with a
pheochromocytoma had a crisis. All patients developing a
crisis had extensive metastatic disease, all patients had liver
metastases, and three also had skeletal metastases. Post-
therapeutic scintigrams showing
177Lu-octreotate uptake in
the metastases are shown in Fig. 1. Also, all patients had
clinically overt hormonal-release-related symptomatology,
like flushing and severe diarrhea. In two of these patients,
hormonal symptoms were so severe that discontinuation of
somatostatin analogue therapy before peptide receptor
radionuclide therapy was impossible. Characteristics of
these patients are shown in Table 2. In all six patients, the
hormonal crisis occurred during the first therapy cycle;
three of the six patients developed the crisis during or
directly after
177Lu-octreotate infusion, and the other three
patients developed the crisis 48 h after
177Lu-octreotate
infusion.
750 Eur J Nucl Med Mol Imaging (2008) 35:749–755The treatment included high-dose octreotide, i.v. fluid
replacement, and other supportive measures (as shown in
Table 2); all patients fully recovered. In all six patients who
developed a hormonal crisis after their first therapy cycle,
additional precautions were taken before the administration
of further therapy cycles, including continuation of somato-
statin analogues, corticosteroids, prolonged observation in
the hospital after therapy, and reduction of administered
dosage of
177Lu-octreotate. Despite these precautions, three
patients developed a hormonal release-induced crisis again
after a subsequent cycle of
177Lu-octreotate.
In two patients, hormonal release could be biochemically
confirmed. We observed massive release of CgA in patient
1. CgA levels increased from 4,379 at baseline to
24,661 μg/l, 24 h after
177Lu-octreotate. Multiple urinary
normetanephrines measurements were performed in patient
6; severely increased excretion of normetanephrines was
observed shortly after therapy with
177Lu-octreotate (Fig. 2)
Fig. 1 Post-therapy scintigrams after
177Lu-octreotate of patient 1 (a),
patient 2 (b), patient 3 (c), patient 4 (d), patient 5 (e), and patient 6 (f).
Upper row Anterior images of the thorax, middle row anterior images
of the abdomen, and lower row anterior images of the pelvic region.
Note that the focal increased
177Lu-octreotate accumulations in liver
metastases in all patients and focal uptake in bone metastases in
patients 1, 2, and 4. In patient 6, there was also uptake in multiple lung
metastases
Table 1 Patients’ characteristics
Tumor type Number of
patients
Somatostatin analogue
pretreatment
Liver
metastases
Bone
metastases
CgA (µg/l)
median (range)
Relevant laboratory findings
median (range)
Carcinoids
-Digestive tract
carcinoid
241 142 223 57 537
(22–787,742)
Urinary 5HIAA (μmol/24 h)
222 (7–2,048)
-Bronchial carcinoid 20 7 16 13 1,252
(35–900,280)
Urinary 5HIAA (µmol/24 h)
191 (15–1,440)
-Thymic carcinoid 4 0 1 1 294
(147–725)
–
Functioning PNETs
-VIPoma 3 0 3 9 153
(22–318)
VIP (pg/ml) 470 (144–710)
-Insulinoma 11 3 8 4 1256
(69–21,509)
–
-Gastrinoma 21 8 19 5 2,282
(111–55,715)
Gastrin (μg/l) 1.2 (0.03–22)
Non functioning
PNETs
124 25 107 24 385
(26–162,710)
–
Neuroendocrine
tumour
of unknown origin
52 10 44 18 400
(23–29,110)
–
metastatic
pheochromocytoma
3 1 1 2 5,666
(928–6,900)
–
Total 479 200 (42%) 422 (88%) 124 (26%)
Digestive tract carcinoid (gastric, duodenum, short bowel, colon, and rectum carcinoids), PNETs (pancreas neuroendocrine tumors) laboratory
normal values: CgA<100 μg/l, 5HIAA<50 μmol/24 h, VIP 25–65 pg/ml, gastrin<0.15 μg/l.
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Hormonal crises after
177Lu-octreotate therapy occur
infrequently; only 6 of 479 patients with GEPNETs and
malignant pheochromocytomas had a crisis. These patients
all had preexisting clinically overt symptoms like flushing
and diarrhea. All six patients had liver metastases, and three
of six patients also had bone metastases. Patients who did
not have a crisis after the first administration of
177Lu-
octreotate also did not develop a hormonal crisis after
subsequent cycles.
In our series, two of three patients treated for metastatic
VIPoma developed a hormonal crisis after
177Lu-octreotate.
VIPomas are associated with a well-defined clinical
syndrome characterized by severe watery diarrhea, hypo-
kalemia, and metabolic acidosis (Verner–Morrison syn-
drome) [11]. Also, 2 of 20 patients treated for metastatic
bronchial carcinoid developed a carcinoid crisis. The
carcinoid syndrome in patients with metastatic bronchial
carcinoids is mediated by 5-hydroxytryptophan, its conver-
sion to serotonin and/or by histamine[12]. The only other
documented carcinoid crisis after radionuclide receptor
therapy also involved a patient with a bronchial carcinoid
[7]. Only one of the 241 patients with a carcinoid
originating from the digestive tract had a hormonal crisis.
One of the three patients treated for a metastatic pheochro-
mocytoma developed a pheochromocytoma crisis. Hormonal
crises in pheochromocytoma patients because of massive
release of catecholamines can lead to multiple clinical features
including (episodic) hypertension or hypotension, myocardial
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Fig. 2 Normetanephrines in 24 h urine (μmol) of patient 6 after
177Lu-octreotate treatment. Note the excessive release of normeta-
nephrines after the first cycle of
177Lu-octreotate. Normal value
urinary normetanephrines: <5.1 μmol/24 h
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[13, 14]. After
131I-MIBG therapy, excessive catecholamine
secretion with the above-mentioned severe symptomatolo-
gy has been reported [15, 16].
No serious hormonal release-induced side effects were
observed in patients with other tumors; there were no
episodes of severe hypoglycemia in patients with metastatic
insulinoma, and none of the patients with metastatic
gastrinoma, non-functioning GEPNETs, or neuroendocrine
tumors of unknown origin developed a hormonal crisis after
177Lu-octreotate.
The exact mechanism of increased hormonal release in
the patients developing a hormonal crisis after
177Lu-
octreotate is not fully elucidated. Several mechanisms
may have accounted for the induction of such a crisis in
our patients: (1) tumor lysis because of beta-irradiation
from
177Lu, (2) discontinuation of short-acting somatostatin
analogues before
177Lu-octreotate administration, (3) emo-
tional stress response to hospitalization and/or therapy, or
(4) administration of amino acids (2.5% arginine and 2.5%
lysine). These amino acids might be used as substrates for
increased hormone synthesis by the tumor cells.
Arguments for tumor lysis because of beta irradiation are
the relatively late onset of complaints (>24 h after therapy)
in patients 2, 3, and 6. Patients 1, 4, and 5 had direct onset
of complaints during
177Lu-octreotate infusion; these crises
cannot be explained by tumor lysis. In patients 4 and 5, the
hormonal crisis might have been induced by emotional
stress in combination with amino acid infusion. These
patients continued their somatostatin analogue therapy. It is
well known that emotional stress can provoke flushing [17];
therefore, it might also be possible that emotional distress,
present in carcinoid patients [18], might have played a role
in the development of the hormonal crises in these patients.
In patient 1, the hormonal crisis might also be related to
discontinuation of somatostatin analogue therapy. When
possible, we stop somatostatin analogues before
177Lu-
octreotate therapy to prevent competitive binding to the
somatostatin receptors with
177Lu-octreotate. The basis for
this approach is the finding of a decreased
111In-octreotide
uptake by the tumor (although not significant) in patients
continuing somatostatin analogue treatment compared to
patients discontinuing somatostatin analogue treatment [19].
Direct receptor-mediated hormonal release by
177Lu-
octreotate seems unlikely. Somatostatin receptor binding
leads to decrease in hormonal secretion in the majority of
patients. Therapy with somatostatin analogues in patients
with metastatic carcinoid tumors results in symptomatic
improvement in more than 70% of the patients and
biochemical response in 50 to 60% of the patients [20, 21].
All patients received further cycles of
177Lu-octreotate
after their first hormonal crisis. When re-treating these
patients, continuation of somatostatin analogues in combi-
nation with corticosteroids is indicated [22, 23]. In one
patient, we halved the administered activity to 3,700 MBq
177Lu-octreotate to decrease potential tumor lysis because
of beta irradiation. Of course, important drawback of such a
treatment protocol is that the tumor-absorbed radiation dose
will also be decreased.
Recommended treatment of patients with hormonal
crises are high-dose somatostatin analogues i.v., i.v. fluids,
corticosteroids, and correction of electrolyte disturbances in
patients with diarrhea and vomiting. Patients with meta-
static pheochromocytoma should also be treated with alpha-
and beta-adrenergic blockade. From the present experience,
we also recommend continuation of somatostatin analogue
therapy in patients with metastatic VIPomas and bronchial
carcinoids who have symptomatology of (atypical) carci-
noid syndrome.
Conclusion
Hormonalcrisesafter
177Lu-octreotate occur infrequently. In
our series, only 6 of 479 patients had such a crisis. Patients
treated for VIPoma or bronchial carcinoids are most at risk.
All patients with a hormonal crisis eventually recovered.
Other less serious side effects shortly after
177Lu-octreotate,
such as nausea, vomiting, and abdominal pain, are more
common and can be controlled by supportive measures.
Generally,
177Lu-octreotate therapy is well tolerated.
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